论文部分内容阅读
本刊讯一种用于预防非典型肺炎的新药———重组人干扰素α -2b喷雾剂于2003年4月24日已获国家食品药品监督管理局批准进入临床试验阶段 ,并即将用于一线医护人员等高危人群。这是国家食品药品监督管理局开辟防治“非典”的“绿色通道”后批准的第1个可在高危人群中进行临床试
News A new drug for the prevention of SARS --- recombinant human interferon alpha -2b spray on April 24, 2003 has been approved by the State Food and Drug Administration into the clinical trial phase, and is about to be used Front-line medical staff and other high-risk groups. This is the first clinical trial approved by the State Food and Drug Administration to establish a “green channel” for prevention and treatment of SARS.